Search
MLN0415
go.drugbank.com/drugs/DB05183ExperimentalMLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists. … In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins.
Oxyphencyclimine
go.drugbank.com/drugs/DB00383ApprovedOxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers.
Lumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigational[A20343] Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute … [A18395] The next most common mutation, G551D, affecting 4-5% of CF patients worldwide, is characterized as a missense mutation, whereby there is sufficient amount of protein at the cell surface, but opening
Pegloticase
go.drugbank.com/drugs/DB09208ApprovedInvestigational[L42425] Pegloticase was approved by the FDA in 2014, and in 2022, the drug label included the co-administration of pegloticase and methotrexate.[L42425] … Pegloticase is a porcine recombinant PEGylated uricase indicated for the treatment of chronic gout in adult patients that do not respond to other types of therapies.
Follicular Non-Hodgkin's Lymphoma Refractory
go.drugbank.com/conditions/DBCOND0110844Synonyms: Follicular Non-Hodgkin's Lymphoma Refractory, Refractory follicular non-hodgkin lymphomaInflammatory, non-infectious pruritic dermatosis
go.drugbank.com/conditions/DBCOND0135056Drugs: HeparinSynonyms: Inflammatory, non-infectious pruritic dermatosisNon-central Nervous System Pathology
go.drugbank.com/conditions/DBCOND0158743Drugs: Olipudase alfaSynonyms: Non-central Nervous System PathologyPrimary Non-metastatic Breast Cancer
go.drugbank.com/conditions/DBCOND0062627Drugs: ChymotrypsinSynonyms: Primary Non-metastatic Breast CancerVaricose veins non-site specific
go.drugbank.com/conditions/DBCOND0027264Drugs: beta-EscinSynonyms: Varicose veins non-site specificDeuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigational[A264108, A264113, A264123] Deuruxolitinib works to block the inflammatory responses caused by JAKs.[L51068] … [A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.